Muhammad Absar (2022) “CLINICAL VALIDATION OF ANKRD36 MUTATIONS AS A NOVEL BIOMARKER FOR MONITORING EARLY PROGRESSION AND TIMELY CLINICAL INTERVENTIONS IN BLAST CRISIS CML”, Journal of Population Therapeutics and Clinical Pharmacology, 29(02), pp. 311–320. doi:10.53555/jptcp.v29i02.4161.